Last $0.20 USD
Change Today 0.00 / 0.00%
Volume 334.2K
As of 8:10 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

ampliphi biosciences corp (APHB) Snapshot

Open
$0.20
Previous Close
$0.20
Day High
$0.20
Day Low
$0.19
52 Week High
03/20/14 - $0.62
52 Week Low
10/14/14 - $0.07
Market Cap
36.5M
Average Volume 10 Days
779.0K
EPS TTM
--
Shares Outstanding
187.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AMPLIPHI BIOSCIENCES CORP (APHB)

Related News

No related news articles were found.

ampliphi biosciences corp (APHB) Related Businessweek News

No Related Businessweek News Found

ampliphi biosciences corp (APHB) Details

AmpliPhi Biosciences Corporation, a biotechnology company, focuses on the discovery, development, and commercialization of novel bacteriophage-based therapeutics. Its lead programs consist of three product candidates, including AmpliPhage-001 for the treatment of P. aeruginosa lung infections in cystic fibrosis patients; AmpliPhage-002 for the treatment of S. aureus infections, including methicillin-resistant S. aureus; and AmpliPhage-004 for the treatment of C. difficile infections. It has a collaboration agreement with Intrexon Corporation to utilize synthetic biology platform for the identification, development, and production of bacteriophage-containing human therapeutics. The company was formerly known as Targeted Genetics Corporation and changed its name to AmpliPhi Biosciences Corporation in February 2011. AmpliPhi Biosciences Corporation was founded in 1989 and is headquartered in Glen Allen, Virginia.

9 Employees
Last Reported Date: 01/5/15
Founded in 1989

ampliphi biosciences corp (APHB) Top Compensated Officers

Chief Scientific Officer
Total Annual Compensation: $225.5K
Compensation as of Fiscal Year 2013.

ampliphi biosciences corp (APHB) Key Developments

AmpliPhi Biosciences Corporation Announces Auditor Changes

On January 20, 2015, AmpliPhi Biosciences Corporation dismissed PBMares, LLP as its independent registered public accounting firm. The company has engaged Ernst & Young LLP as its new independent accountant as of January 20, 2015.

AmpliPhi Biosciences Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

AmpliPhi Biosciences Corporation reported earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported net income of USD 19.4 million against net loss of USD 43.9 million a year ago. Loss from operations was USD 4.9 million against USD 2.3 million a year ago. For the nine months, the company reported net income of USD 22.8 million against net loss of USD 58.3 million a year ago. Loss from operations was USD 11.2 million against USD 9.8 million a year ago.

AmpliPhi Biosciences Corporation - Shareholder/Analyst Call

To provide current and prospective investors highlights of the company’s accomplishments during 2014; and to provide an overview of corporate initiatives for the year moving forward

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
APHB:US $0.20 USD 0.00

APHB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for APHB.
View Industry Companies
 

Industry Analysis

APHB

Industry Average

Valuation APHB Industry Range
Price/Earnings 2.3x
Price/Sales 120.8x
Price/Book 3.2x
Price/Cash Flow 1.6x
TEV/Sales 62.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AMPLIPHI BIOSCIENCES CORP, please visit www.ampliphibio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.